Please login to the form below

Not currently logged in
Email:
Password:

Anda

This page shows the latest Anda news and features for those working in and with pharma, biotech and healthcare.

Amarin shares tumble following Vascepa patent loss

Amarin shares tumble following Vascepa patent loss

Amarin strongly disagrees with the ruling and will vigorously pursue all available remedies, including an appeal of the court's decision and a preliminary injunction pending appeal to, if an ANDA

Latest news

  • Teva acquires Allergan’s generics operations in $38.8bn deal Teva acquires Allergan’s generics operations in $38.8bn deal

    The Israeli pharmaceutical firm currently has over 400 products awaiting FDA and Abbreviated New Drug Application (ANDA) approval in the US, and expects to launch 1, 500 generics worldwide in 2017. ... Once the transaction has been completed, Anda will

  • Piramal sells clinical research arm to Indoco Piramal sells clinical research arm to Indoco

    Apart from reducing cost and ensuring time-bound outcome of studies, the CRO would be a perfect fit to our existing R&D efforts, including facilitation of ANDA/Dossier filings.”.

  • UCB files Vimpat patent claims against 15 companies UCB files Vimpat patent claims against 15 companies

    ANDA) by Aurobindo to market its own version of Vimpat (lacosamide) in the US. ... Other companies have also submitted their own ANDAs, however, encouraged by the prospect of a 180-day exclusivity period for the first generic product to successfully

  • Bayer sues Glenmark over its skin disorder generic Bayer sues Glenmark over its skin disorder generic

    Glenmark filed an Abbreviated New Drug Application (ANDA) to the US FDA for its own version of azeliac acid gel, which is approved for the treatment of inflammatory papules and pustules ... Despite the lawsuit and risk of related penalties, by becoming

  • Par buys Anchen in $410m deal

    California-based Anchen has five commercialised products, 27 abbreviated new drug applications (ANDAs) on file with the US Food and Drugs Administration (FDA), five of which are believed to be

More from news
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 652. Teva and Allergan/ Impax Laboratories. 15 marketed generics, an approved generic drug and a pipeline generic drug; inc return to Impax of rights to its pending ANDA for ... 8 generic drugs - filed ANDAs pending approval and an

  • Pharma deals in July 2015 Pharma deals in July 2015

    66 ANDA filings and a pipeline of over 65 products.

  • Pharma deals during April 2014 Pharma deals during April 2014

    platform of specialty and generic products including 629 ANDAs.

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    33. Pernix Therapeutics / Breckenridge Pharma. Acquisition. 11 Abbreviated New Drug Applications (ANDAs), certain ANDAs in various stages of development, 7 marketed products.

  • Pharma deals during August 2013 Pharma deals during August 2013

    In its deal with Pernix Therapeutics, Breckenridge Pharmaceutical adds further generic assets including 11+ ANDAs and 7 previously marketed products, covering solid oral products and unique dosage forms, to its already

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics